# The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania

> **NCT00216554** · PHASE4 · COMPLETED · sponsor: **Janssen Korea, Ltd., Korea** · enrollment: 118 (actual)

## Conditions studied

- Bipolar Disorder

## Interventions

- **DRUG:** risperidone

## Key facts

- **NCT ID:** NCT00216554
- **Lead sponsor:** Janssen Korea, Ltd., Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-09
- **Primary completion:** —
- **Final completion:** 2006-03
- **Target enrollment:** 118 (ACTUAL)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216554, "The Safety and Efficacy of Risperidone as Adjunctive Therapy to Mood Stabilizers in the Long-term Treatment of Bipolar Mania". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00216554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*